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Recently, WHO, EU, Japan and Canada have published guidelines on biosimilar/follow-on biologics. While
there seems to be no signiﬁcant difference in the general concept in these guidelines, the data to be
submitted for product approval are partially different. Differences have been noted in the requirements
for comparability studies on stability, prerequisites for reference product, or for the need of compara-
bility exercise for determination of process-related impurities. In Japan, there have been many discus-
sions about the amount and extent of data for approval of follow-on biologics. We try to clarify the
scientiﬁc background and rational for regulatory pathway of biosimilar/follow-on biologics in Japan in
comparison with the guidelines available from WHO, EU and Canada. In this article, we address and
discuss the scientiﬁc background underlying these differences to facilitate the harmonization of follow-
on biologic principles in the guidelines in future.
 World Health Organization 2011. All rights reserved. The World Health Organization has granted the
Publisher permission for the reproduction of this article.1. Introduction
Over the last three decades, many biotechnology products have
been developed and marketed as new therapeutics for difﬁcult-to-
treat diseases. Consequently, these products have become essen-
tials for the treatment of many serious diseases. However, the cost
of these products has often been high, which in conjunctionwith an
expansion of biotechnological products has contributed to an
increase in health-care costs.
Recently, the expiration of patents and/or data protection for the
ﬁrst major group of innovator’s biotechnology products has
ushered in an era of products that are designed to be ‘similar’ to
a licensed innovator product [1e4]. These products rely, in part, for
their licensing on prior information and experiences regarding
safety and efﬁcacy obtainedwith the innovator products. Therefore,
the clinical experience and established safety proﬁle of the inno-
vator products contributes to the development of similar biotech-
nology products (namely follow-on biologics in Japan and
biosimilar in EU) [5e7]. The amount and extent of data required for
the licensing of biosimilar/follow-on biologic products is likely to
be less than is normally required for the innovator products.lth Sciences, 18-1 Kamiyoga,
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ll rights reserved. The World HealthJapanese regulatory authority has been confronted with the new
challenge of regulating biosimilar/follow-on biologic products. To
ensure the quality, safety and efﬁcacy of biosimilar/follow-on biologic
products, Japan has published a guideline [8] for quality, safety and
efﬁcacy of biosimilar/follow-on biologics based on the similarity
concept outlined by the EMA. Following the adoption of the guideline,
two follow-onbiologicproductshavebeenapprovedormarketed, and
more than tenproductsare indevelopment in Japan.WHOandCanada
have also published guidelines for similar biotherapeutic products
(SBPs) and subsequent entry biologics (SEB) for products termed
biosimilar/follow-on biologics [9,10]. These guidelines have generally
similar fundamental concepts and similar regulatory framework for
the licensure of biosimilar/follow-on biologics. However, several
regulatory requirements for these products seem to be different from
each other. Therefore, it is very interesting to compare the require-
ments of each guideline, and help in the harmonization of regulatory
pathway for biosimilar/follow-on biologic products.2. Japanese guideline for follow-on biologics
The Japanese regulatory authority published the guideline on
follow-on biologics and the related notiﬁcations in March of 2009.
The guideline indicates that biotechnology-derived products
generally have unique characteristics such as structural complexity,
being comprised of several functional domain sites, with speciﬁc
bioactivity or stability and immunogenicity attributes. Further-
more, quality attributes of biotechnology-derived products deter-
mine the highly complex characteristics of the desired product, theOrganization has granted the Publisher permission for the reproduction of this article.
Table 1
Scope of the Japanese guideline.
Decision Products Reasons Notes
Yes Recombinant plasma
proteins
There is no reason to exclude recombinant
plasma proteins from the scope, even though
some proteins have a highly complicated structure
Some patients might prefer non- recombinant products.
Blood product supply might be affected, even though an
overlapped product development ensures the consistent supply
Recombinant vaccines Well characterized recombinant vaccine can be
possibly developed as follow-on biologics
Vaccine is administrated to healthy humans
Lot-to-lot variation of adjuvant activity is relatively large
PEGylated recombinant
proteins
Conjugates are in the scope as is in ICH Q6B Development of PEGylated protein as follow-on biologics might
be difﬁcult due to the structural complexity
No Synthetic peptides Impurity proﬁle is different from that of
recombinant proteins
Synthetic peptides can be generic drugs, because the desired
product can be easily deﬁned by structural analyses
No Polyglycans Characterization is difﬁcult Several polyglycan products have been approved as generic
drugs in Japana
Case by case Non-recombinant proteinsa Proteins that are highly puriﬁed and characterized
could be developed as follow-on biologics
Several urine-derived protein products have been approved
as generic drugs in Japan
a e.g. proteins such as isolated from tissues or body ﬂuids.
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process-related impurities which constitute the product. As
a result, it is muchmore difﬁcult to prove that the quality attributes
of a follow-on biologic are identical to that of the approved inno-
vator product as compared with small chemically synthesized
drugs. Therefore, the generic approach used for small chemically
synthesized drugs cannot be applied to these products. The
guideline deﬁnes a follow-on biologic as a biotechnological drug
product, which is comparable to an approved biotechnology-
derived product of an innovator company. Therefore, a sponsor
should submit the data to prove that their product is highly similar
and that existing knowledge is sufﬁciently predictive to ensure that
any differences in quality attributes between their product and the
reference product have no adverse impact on the drug product or
on its safety or efﬁcacy.
2.1. Scope and paradigm of Japanese guideline
The scope of Japanese guideline is summarized in Table 1; the
focus is predominantly on recombinant protein products as follow-
on biologics. The complexity of some biotechnology-derived
products will make it difﬁcult to develop them as follow-on bio-
logics [8]. However, since the current technology to analyze
biotechnology products is very rapidly progressing, it maybe
possible to analyze the comparability of these complex products in
near future. Therefore, no recombinant protein products are
excluded as scope of guideline and until recently, polyglycans such
as low-molecular weight heparin have unlike EU, been excluded
from this guideline.Fig. 1. Dossiers of follow-on bParadigm of data to be required for development of follow-on
biologics is illustrated in Fig. 1. Since dossiers containing all data
of the innovators products may not be disclosed, the sponsor
developing a follow-on biologic should independently establish the
robust manufacturing process to ensure the consistency of the
product is the same as in the case for approval of new biologics. In
addition, the follow-on biologic product should be fully character-
ized independently as same as for new biologics.
The sponsor should compare the quality attributes of the
product with the reference innovator product as far as possible and
provide the data demonstrating the high similarity in quality
attributes with the reference innovator product. On the basis of
these data, the sponsor should evaluate the comparability of the
follow-on biologic with its reference product through non-clinical
and clinical studies.
Even though the biosimilar/follow-on biologics may be devel-
oped with abbreviated non-clinical and clinical data, the sponsor
should submit all data according to the ICH CTD guideline (ICH M4)
[11] for new drugs. The data concerning the comparability of
quality attributes with the reference innovator products are rec-
ommended to be included in the 2.3.R of module 2 in CTD (Fig. 2).
Concerning the comparability exercise, the application of ICH
Q5E guideline to comparability studies on follow-on biologics has
been discussed. The objective of ICH Q5E guideline is to provide the
principles for assessing the comparability of biotechnological/bio-
logical products where changes are made on manufacturing
processes. Innovator manufacturers can compare both products
head-to-head in such a case. Since the information of innovator’siologics to be submitted.
Fig. 2. Diagrammatic representation of the organization of follow-on biologics
according to the ICH CTD common technical document.
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can not always be applied to the evaluation of follow-on biologics.
Therefore, based on the concept of Q5E, sponsors developing
follow-on biologics should consider the comprehensive approach
including comparability studies and other approaches that utilize
public information or existing experiences.
2.2. Development and optimization of manufacturing process
As for a new biotechnological product, a well-deﬁned
manufacturing process should be established, and extensive char-
acterization studies should be conducted to reveal the molecular
and quality attributes of the follow-on biologic.
If the host cell line used for the production of reference inno-
vator product is disclosed, it is highly recommended to use the
same cell line. For the establishment and characterization of the cell
banks, ICH Q5A, Q5B, Q5D guidelines should be referred. It is rec-
ommended to adopt the manufacturing processes that potentially
improve the safety of the product but these should not affect
efﬁcacy.
During the development of manufacturing process, alteration
and optimization of the puriﬁcation process may be necessary to
produce a product that is similar in quality attributes to the refer-
ence product (Fig. 3). Much effort may be needed for theFig. 3. Model of optimization of manufacturing proptimization of manufacturing processes during the development
of follow-on biologics.
2.3. Characterization and evaluation of quality attributes of follow-
on biologics
The quality attributes of follow-on biologics which are manu-
factured with stable and robustly-established manufacturing
processes should be as thoroughly characterized as new recombi-
nant protein products.
The comparability of quality attributes with those of reference
innovator biologics should be evaluated as far as possible and
applicable. The comparability exercise should include structural
characterization and physicochemical properties, biological activi-
ties and other immunological properties to examine the similarity
of quality attributes.
The acceptable criteria for differences in quality attributes will
vary depending on the characteristics of the product and the clin-
ical purpose and dosage form in clinical use. Assessment of the
variation of quality attributes observed in different batches of the
innovator product will provide the basis of acceptable criteria for
the biosimilar products (Fig. 4). However, it is not always feasible to
analyze the variation of quality attributes of innovator products,
because of the limitation of accessibility to various lots of innovator
products.
On the basis of data obtained from the comparability exercise of
quality attributes, demonstration of the high similarity in quality
attributes with the reference medicinal product is required.
3. Non-clinical studies and clinical study
Demonstration of high similarity of the candidate follow-on
biologic with the reference innovator products enables the utili-
zation of experiencing reference products, because follow-on
biologics are generally developed long after the approval of
innovator products. Therefore, not only the data submitted for the
approval of the innovator products but also the safety and efﬁcacy
data accumulated from the treatment of many patients provides
important and useful information about the product. Based on the
innovator’s experiences, the sponsor may develop the follow-on
biologics with abbreviated data from non-clinical and clinical
studies.
As a minimum requirement, the sponsor should evaluate the
safety of a follow-on biologic for human use prior to entering intoocess according to the comparability studies.
Lot –to-lot variations of the quality 
attributes of the innovator products
E
v
b
pCan representative lots be accessed?
valuation of 
ariability
Lot-to-lot variations of follow-on 
biologics
etween both 
roducts
Fig. 4. Acceptance criteria for the variation of the quality attributes of follow-on biologics. It is not always feasible to analyze the variation of quality attributes of innovator products,
because of the limitation of accessibility to various lot of inovator products.
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ductive toxicity studies are not required for toxicology studies on
follow-on biologics, if applicable. Single dose toxicology study
could be conducted as a part of repeated dose toxicology study as
well as evaluation of local tolerance.
On the other hand, comparability studies may be useful and
appropriate to verify the similarity of pharmacological effects
between the follow-on biologic and reference product.
In general, it is difﬁcult to verify the comparability of a follow-on
biologic with the originator biologic based on data from the quality
attributes and non-clinical studies alone. Therefore, the sponsor
should evaluate the comparability of a follow-on biologic with the
innovator product in clinical studies.
While there is sufﬁcient data to assure the comparability in
clinical endpoint has been obtained by clinical pharmacokinetic
(PK), pharmacodynamic (PD) and/or PK/PD studies, further clinical
studies may be reduced in some cases. Arato et al have reported
case studies about clinical studies conducted in Japan and discussed
the comparability criteria for clinical studies [12].
In certain cases, it may be possible to extrapolate from one
indication to the other indications of the originator biologic used as
the reference product. The extrapolation of indications is limited to
the indications of the reference product and does not include the
indications of other approved recombinant protein products with
similar indicators.Table 2
Comparison of requirement for evaluation of SBPs between WHO and Japan.
Japan
Scope Recombinant protein products
Category of application
for approval
Follow-on biologics different from new
drugs or generic drugs
Manufacturing process
and CMC
Manufacturing process as well as new drugs,
full data of CMC
Reference products Same reference product approved in Japan
through development
Comparative studies Q, NC, C
Not always required to evaluate safety about
process-related impurities
Stability tests Expire period: Real time/real temperature
Optional: Compare accelerated stability
of SBP and RBP
Interchangeability/
substitutability
Interchangeability is accepted,
Substitutability is not suitable
Ab production Enough period
Others
Q: quality attributes; NC: non-clinical study; C: clinical study.4. Comparison of the guideline EU, WHO and Japanese for the
follow-on biologics
A comparison of the guidelines EU, WHO and Japanese for the
follow-on biologics is summarized in Table 2. The scope of each
guideline is virtually identical as they all focus on recombinant
protein products, except for low-molecular heparin in EU. In terms
of Chemistry, Manufacturing and Control (CMC), all guidelines
require the establishment of a robust manufacturing process to
ensure the product consistency (as expected for new drugs), and
the necessity for full data to characterize the quality attributes of
a follow-on biologic.
4.1. Reference products for follow-on biologics
The Japanese guideline clearly describes the deﬁnition of
reference products (innovator products) as well as EMA guideline;
the sponsor should demonstrate comparability with the original
innovator biologic through both non-clinical and clinical studies.
Furthermore, the original biologic should be already approved in
Japan, the same product should be used throughout the develop-
ment period of the follow-on biologics (i.e., during the character-
ization of quality attributes, non-clinical and clinical studies).
On the other hand, in WHO and Health Canada guidelines,
innovator products which are approved by the regional regulatoryWHO EU
Recombinant protein products Mainly recombinant protein products
Regulation in each nation Biosimilar products
Manufacturing process as well as
new drugs, full data of CMC
Manufacturing process as well as
new drugs, full data of CMC
May not be country speciﬁc Same reference product approved
in EU through development
Q, NC, C Q, NC, C
Expire period: Real time/real
temperature
Should compare accelerated
stability of SBP and RBP
performing stress and accelerated
stability studies
Not described Interchangeability is accepted,
but not substitutability
Enough period Recommendation (1yr)
International harmonization
Table 3
Nonproprietary & Brand Names of follow-on biologics.
Nonproprietary Name:
BBBBB (genetical recombination) [     Biosimilar 1]
Brand Name:      BS Inj Content Company-Name
     excludes “genetical recombination” from the Nonproprietary Name
of original biologic
[Example]
Nonproprietary Name: Epoetin Kappa (Genetical Recombination)
[Epoetin Alfa Biosimilar 1].
Brand Name: Epoetin Alfa BS Inj 750 “JCR” (“JCR” is an example of the
company name).
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reason for this is that all countries can not always access the rele-
vant innovators product.
4.2. Stability test for follow-on biologics
To evaluate the stability of follow-on biologics, long-term, real-
time, and real-condition stability studies are required according to
the ICH Q5C guideline on “Stability Testing of Biotechnological/
Biological Products”. Since either excipients and/or buffer compo-
sition of drug substance or pharmaceutical formulation of follow-
on biologics are not necessarily identical to those of innovator
products, identical storage condition and storage period of follow-
on biologics is not always required to follow the reference medic-
inal products in Japan. Furthermore, a comparison of stability with
the reference medicinal product will not be essential, but in some
cases, a comparison of stability with reference medicinal product,
such an accelerated stability test, provides some useful information
about the difference of quality attributes, such as degradation
products. Therefore, a comparison of the stability of a follow-on
biologic with the reference innovator product as a strategy for
development of follow-on biologic is not always necessary.
4.3. Evaluation of safety of process-related impurity
There are some differences in the requirement of toxicology
study for impurity in follow-on biologics between EU, WHO and
Japan. The Japanese guideline describes that since the impurity
proﬁle of a follow-on biologic may be assumed to be different from
that of the original biologic in many cases, it is not required to
evaluate the safety of impurities in the follow-on biologic through
non-clinical studies without comparison to the original biologic.
Culture method, including medium composition such serum,
growth factor or additives, and puriﬁcation method will remark-
ably affect the proﬁle of the process-related impurity in biotech-
nology products. It is recognized that it is very difﬁcult to evaluate
the comparability of the impurity proﬁle between a follow-on
biologic and reference product from the viewpoint of quality and
quantity.
4.4. Interchangeability and substitutability
After the marketing of follow-on biologics, the change of
prescription from the innovator products to follow-on biologics
(interchangeability) is generally permitted. On the other hand, it is
very important to assure the traceabilityof anyadverseevents arisingduring the respective surveillance period. Therefore, it is strongly
recommended to avoid automatically substituting (substitutability)
the originator biologics with the follow-on biologics throughout
a certain period of patient treatment.
4.5. Naming of follow-on biologics in Japan
Japanese notiﬁcation for naming of follow-on biologics has been
published at the same time of guideline for follow-on biologics. The
notiﬁcation describes the Nonproprietary & Brand Names of follow-
on biologics (Table 3).
For Nonproprietary Names, Biosimilar should be sufﬁxed to the
Nonproprietary name of the original biologic at the time of the
approval. The individual products are determined to be the follow-
on biologics through a reviewing process for the approval.
On the other hand, for brand name, the dosage form, dosage,
and company name should be attached to the nonproprietary
name.
5. Conclusion
The approval of follow-on biological/biosimilar will be the
matter of regional regulatory authorities as several follow-on bio-
logics/biosimilar have been marked globally. Since the follow-on
biologics/biosimilar are generally approved with the abbreviated
clinical data, the accumulation of safety data during the post
marketing surveillance and sharing the safety data with each
regulatory authority are very important. Therefore, it is desirable to
globally harmonize how to collect the safety data.
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